Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Share-based Compensation (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Share-based Compensation for 7 consecutive years, with $10.0 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 0.99% to $10.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.9 million through Dec 2025, up 4.71% year-over-year, with the annual reading at $44.9 million for FY2025, 5.38% up from the prior year.
  • Share-based Compensation hit $10.0 million in Q4 2025 for Harmony Biosciences Holdings, down from $11.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $12.5 million in Q1 2025 to a low of $3.3 million in Q1 2021.
  • Historically, Share-based Compensation has averaged $8.1 million across 5 years, with a median of $7.9 million in 2023.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 725.81% in 2021 and later decreased 4.18% in 2025.
  • Year by year, Share-based Compensation stood at $4.4 million in 2021, then surged by 65.64% to $7.3 million in 2022, then rose by 22.08% to $8.9 million in 2023, then increased by 13.64% to $10.1 million in 2024, then fell by 0.99% to $10.0 million in 2025.
  • Business Quant data shows Share-based Compensation for HRMY at $10.0 million in Q4 2025, $11.0 million in Q3 2025, and $11.5 million in Q2 2025.